<DOC>
	<DOCNO>NCT02432690</DOCNO>
	<brief_summary>This open label , single-arm , phase II study . The study population adult patient asymptomatic recurrent ovarian cancer elevation CA-125 level .</brief_summary>
	<brief_title>A Study BBI503 Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Key inclusion criterion : 1 . Histological cytological confirmation epithelial ovarian , primary peritoneal , fallopian cancer previous time point . 2 . Recurrent relapse completion initial therapy epithelial ovarian , primary peritoneal , fallopian cancer previous time point ( include completion surgery without postoperative chemotherapy , include maintenance chemotherapy ) 3 . Elevation CA125 accord follow definition : Patients elevate CA125 chemotherapy normalization CA125 with/after chemotherapy must show evidence CA125 great equal 2 time upper limit normal ( ULN ) 2 occasion least 1 week apart Patients elevate CA125 cancer chemotherapy , never normalize , must show evidence CA125 great equal 2 time nadir value 2 occasion least 1 week apart Patients CA125 normal range cancer chemotherapy must show evidence CA125 great equal 2 time ULN 2 occasion least 1 week apart For patient received subsequent treatment recurrent cancer , `` chemotherapy '' criterion refers recent round chemotherapy . 4 . Patients history ovarian cancer asymptomatic document previous CA125 level may enroll CA125 great three time ULN two occasion , least one week apart 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 Key exclusion criterion : 1 . Symptoms ( ≤ grade 1 fatigue , anxiety , depression , psychological symptom ) , opinion treat oncologist , direct result cancer recurrence . ( Examples symptom would preclude enrollment include unintentional weight loss , ≥ grade 2 fatigue , new abdominal pain unrelated operative procedure ovarian malignancy . ) 2 . Receiving investigational agent would consider treatment primary neoplasm . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent ≤14 day first dose study drug 3 . Major surgery ≤28 day start treatment 4 . History another primary malignancy associate diseasefree interval le 5 year , except curatively treat basal cell squamous cell carcinoma skin situ cancer cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasms</keyword>
</DOC>